[HIGHLIGHTS] FDA approves use of weight-loss drug Wegovy to reduce risk of heart attack and stroke

FDA approves use of weight-loss drug Wegovy to reduce risk of heart attack and stroke. Approval could convince more companies and insurers to pay for the popular drug.

WeGovy contains semaglutide, the same active ingredient in the popular diabetes medication Ozempic. Heart attacks are the leading cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC) The decision comes after, in an advanced clinical trial with more than 17,000 adults, Novo Nordisk found that WegovY reduces the risk ofHeart attacks and strokes by 20%.